Tyruko (natalizumab-sztn) / Sandoz, Novartis, Genefar  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tyruko (natalizumab-sztn) / Genefar, Sandoz
Antelope, NCT04115488 / 2018-004751-20: Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

Completed
3
265
Europe, RoW
Intravenous (IV) infusions
Polpharma Biologics S.A.
Relapsing-Remitting Multiple Sclerosis (RRMS)
08/21
02/22

Download Options